Immunovant (IMVT) has decided to discontinue the development of IMVT-1402 for cutaneous lupus erythematosus (CLE) after its proof-of-concept trial failed to meet the primary endpoint. This decision, despite positive safety trends, led to a decline in shares for both Immunovant and its parent company, Roivant Sciences (ROIV), as the program's termination impacts future revenue potential in this specific indication.
Immunovant announced the cessation of its IMVT-1402 program for cutaneous lupus erythematosus (CLE) after the drug failed to achieve its primary endpoint in a proof-of-concept trial. This is a significant setback for Immunovant, as it eliminates a potential revenue stream and forces a reallocation of resources. Both Immunovant and its parent company, Roivant Sciences, saw their stock prices fall in premarket trading, reflecting investor disappointment. While the drug showed positive safety and some numerical trends, the lack of statistical significance and the competitive landscape led to the decision. Immunovant will now focus on other autoimmune conditions for IMVT-1402, presenting a long-term opportunity if those trials succeed, but a short-term risk as investors digest this failure.